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Key messages
What is already known about this subject?
 ► Previous studies have found that no single test 
has sufficient predictive power to detect sight- 
threatening eye disease. Consequently, population 
screening for single sight- threatening disorders has 
not been shown to be cost effective.
What are the new findings?
 ► This study found that a subset of screening tests 
that evaluate ocular structure and function had good 
discriminatory power for detecting sight- threatening 
eye disease in a cohort of elderly participants re-
cruited from primary care.
How might these results change the focus of 
research or clinical practice?
 ► The results provide useful data to inform the devel-
opment of larger, multicentre population studies to 
evaluate the effectiveness and cost- effectiveness of 
screening for eye disease in the elderly.
AbsTrACT
background/aims To determine the performance of 
combinations of structural and functional screening tests 
in detecting sight- threatening eye disease in a cohort of 
elderly subjects recruited from primary care.
Methods 505 subjects aged ≥60 years underwent 
frequency doubling technology (FDT) perimetry, iVue 
optical coherence tomography (iWellness and peripapillary 
retinal nerve fibre layer (RNFL) scans) and intraocular 
pressure with the Ocular Response Analyzer, all performed 
by an ophthalmic technician. The reference standard was 
a full ophthalmic examination by an experienced clinician 
who was masked to the index test results. Subjects were 
classified as presence or absence of sight- threatening 
eye disease (clinically significant cataract, primary 
open- angle glaucoma, intermediate or advanced age- 
related macular degeneration and significant diabetic 
retinopathy). Univariate and multivariate logistic regression 
analyses were used to determine the association between 
abnormal screening test results and the presence of sight- 
threatening eye disease.
results 171 subjects (33.8%) had one or more sight- 
threatening eye diseases. The multivariate analysis 
found significant associations with any of the target 
conditions for visual acuity of <6/12, an abnormal FDT 
and peripapillary RNFL thickness outside the 99% normal 
limit. The sensitivity of this optimised screening panel was 
61.3% (95% CI 53.5 to 68.7), with a specificity of 78.8% 
(95% CI 74.0 to 83.1), a positive predictive value of 59.5% 
(95% CI 53.7 to 65.2) and an overall diagnostic accuracy 
of 72.9% (95% CI 68.8 to 76.8).
Conclusions A subset of screening tests may provide an 
accurate and efficient means of population screening for 
significant eye disease in the elderly. This study provides 
useful preliminary data to inform the development of 
further larger, multicentre screening studies to validate this 
screening panel.
InTroduCTIon
Population ageing is leading to substantial 
increases in visual impairment.1 Sight loss 
from cataract, age- related macular degen-
eration (AMD), diabetic retinopathy and 
uncorrected refractive error affects approx-
imately two million of the UK population.1 
The burden of sight loss disproportionally 
affects the elderly,2 with one in five people 
aged 75 years or over, and one in two 
people aged 90 years and over living with 
sight loss.3 Poor access to routine NHS sight 
testing in ‘at- risk’ populations, coupled 
with the absence of symptoms in the early 
stages of many of these diseases, can lead to 
delayed or late presentation.4 5 Given that 
a significant proportion of sight loss can be 
prevented through early detection and timely 
therapeutic interventions, it is likely that 
investment in prevention and screening for 
sight- threatening eye disease would lead to 
improved socioeconomic outcomes.6
Previous studies have examined the predic-
tive power of individual screening tests to 
detect eye disease in both clinic- based and 
general populations and have found that no 
single test has sufficient predictive power to 
detect sight- threatening eye disease.7–10 By 
contrast, the performance of combining 
screening tests has shown greater promise. 
For example, Kopplin and Mansberger eval-
uated a test battery performed by ophthalmic 
 o
n
 M
arch 2, 2020 by guest. Protected by copyright.
http://bmjophth.bmj.com/
BM
J O
pen O
phth: first published as 10.1136/bmjophth-2019-000347 on 4 December 2019. Downloaded from 
2 Fidalgo BR, et al. BMJ Open Ophth 2019;4:e000347. doi:10.1136/bmjophth-2019-000347
Open access
Figure 1 Study flow diagram. The number of eye conditions exceeds the number of participants due to ocular comorbidity. 
AMD, age- related macular degeneration; FDT, frequency doubling technology; ORA, Ocular Response Analyzer; POAG, primary 
open- angle glaucoma; SD- OCT, spectral domain optical coherence tomography.
technicians for the detection of visually significant eye 
disease in a population of American Indian and Alaskan 
Native participants.11 The authors identified that visual 
acuity worse than 6/12 (20/40), abnormal or poor- 
quality non- mydriatic photography, abnormal frequency 
doubling technology (FDT) perimetry, and abnormal 
or poor- quality confocal scanning laser ophthalmoscopy 
had the greatest predictive value.
We have previously demonstrated that combining struc-
tural and visual- function tests improves case detection of 
primary open- angle glaucoma (POAG) in a representa-
tive population of elderly subjects in the community.12 
The aim of the current study was to extend this analysis 
to determine the performance of screening test combi-
nations in detecting sight- threatening eye disease in the 
same population.
MeTHods
study population
This prospective diagnostic accuracy study was conducted 
in an urban community eye clinic in London, UK, between 
September 2012 and September 2013. Men and women 
aged ≥60 years were invited to participate via a written 
invitation sent to community groups and local optometry 
practices. There were no exclusion criteria, and partic-
ipants with prediagnosed ocular disease were included. 
Participants underwent a series of technology- based 
index tests followed by a reference standard ophthalmic 
examination (detailed further), conducted on the same 
day, to establish ocular health status. Figure 1 shows the 
study flow diagram.
Index tests
The technology- based assessment comprised the measure-
ment of intraocular pressure (IOP) using the Ocular 
Response Analyzer (ORA; Reichert Ophthalmic Instru-
ments, Depew, NY, USA), assessment of visual fields with 
first- generation FDT perimetry (FDT; Carl Zeiss Meditec, 
Dublin, CA, USA) in C-20–5 suprathreshold mode and 
measurement of structural parameters of the macula 
and optic nerve head by spectral domain optical coher-
ence tomography (SD- OCT) (iVue SD- OCT; Optovue, 
Fremont, CA, USA). Two optical coherence tomography 
(OCT) scans were performed: the proprietary iWell-
ness protocol, which reports full retinal thickness and 
ganglion cell complex (GCC) thickness with normative 
comparisons, and a peripapillary retinal nerve fibre 
layer (RNFL) scan. An experienced ophthalmic techni-
cian performed all index tests with no prior knowledge 
of the subjects’ ocular status or findings from the refer-
ence standard ophthalmic examination. Thresholds of 
abnormality for the index tests were prespecified and 
were based on commonly used cut- offs reported in the 
literature or manufacturers’ suggested thresholds, based 
on comparisons with the instruments’ internal normative 
database. For the FDT, an abnormal result was defined 
using two thresholds: ≥1 location missed at either 
the p<5% or the p<1% significance level. The test was 
repeated once if one or more locations were missed or 
if the result was unreliable. For the SD- OCT, the defined 
cut- off for abnormality was any parameter falling outside 
the 99% normal limit based on the manufacturer’s inte-
grated normal database; IOP>21 mm Hg was used as the 
threshold for the ORA.
reference standard ophthalmic examination
All participants underwent a standard ophthalmolog-
ical examination conducted by an experienced clinician 
who was trained and validated in glaucoma according to 
standard UK practice and also completed grader accred-
itation in diabetic retinopathy and AMD at the Reading 
Centre, Moorfield’s Eye Hospital, London, UK. The refer-
ence standard examination was conducted on the same 
day as the index tests, and the clinician was masked to the 
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Table 1 Diagnostic criteria used for classifying the most prevalent eye diseasesn
Definitions of eye diseases
Eye condition Classification Description
POAG Definite 1. Open anterior chamber angle
2. Localised absence of neuroretinal rim, cup:disc 
ratio≥0.7, or interocular asymmetry in vertical cup:disc 
ratio≥0.2 in similar- sized discs
3. Presence of a concordant glaucomatous field defect 
based on criteria amended from Hodapp et al15
Suspect Features of glaucomatous optic neuropathy but with normal 
or equivocal fields or subjects with glaucomatous visual 
field defects but without concordant disc damage
Diabetic retinopathy* Background retinopathy (R1) Microaneurysms, dot and blot haemorrhages, venous loops 
and cotton wool spots
Preproliferative retinopathy (R2) Venous beading, venous reduplication, multiple blot 
haemorrhages, intraretinal microvascular abnormality
Proliferative retinopathy (R3) Active proliferative retinopathy
Maculopathy (M1) Groups of exudates, clinically significant macular oedema
AMD Early AMD (AREDS category 2)34 Several small drusen or a few medium- sized drusen in one 
or both eyes
Intermediate AMD (AREDS category 3)34 Many medium- sized drusen or one or more large drusen 
(≥125 µm) in one or both eyes
Advanced AMD
(AREDS category 4)34
Geographical atrophy of the RPE involving the foveal centre 
or any features of neovascular AMD
Clinically significant 
cataract
LOCS II grading35 LOCS II score of ≥2 for cortex, posterior subcapsular, 
nuclear or hypermature cataract
*The grading system for diabetic retinopathy was based on that used by the UK NHS Diabetic Eye Screening Programme (https://www.gov.
uk/government/publications/diabetic-eye-screening-retinal-image-grading-criteria).
AMD, age- related macular degeneration; AREDS, Age- Related Eye Disease Study; LOCS II, Lens Opacities Classification System II; POAG, 
primary open- angle glaucoma.
index test results. The reference examination consisted 
of LogMAR best- corrected visual acuities, full anterior 
segment assessment by slit- lamp biomicroscopy, assess-
ment of limbal anterior chamber depth (with potentially 
occludable angles examined using gonioscopy), measure-
ment of IOP using the Goldmann applanation tonometer, 
posterior segment examination through dilated pupils 
using indirect ophthalmoscopy and threshold visual field 
testing with a Humphrey field analyzer using Swedish 
Interactive Thresholding Algorithm (SITA) standard 
24–2 pattern. The diagnostic criteria classifying the most 
commonly identified eye diseases are given in table 1.
sample size calculation
The sample size was originally determined based on an 
anticipated sensitivity of 0.75 to detect POAG13 with a 
minimal acceptable precision of ±0.25 with 0.95 prob-
ability. This would require approximately 50 cases, and 
based on an anticipated prevalence of POAG in an 
elderly population of 8%–10%,14 it was therefore esti-
mated that at least 500 participants would be needed. For 
this secondary analysis, we prospectively determined that 
a similar number of cases of intermediate and advanced 
AMDs would be required, based on a disease prevalence 
of 8% in the target population,14 an anticipated index 
test sensitivity of 0.75 and an equivalent level of preci-
sion.11
statistical analysis
Summary statistics were tabulated and standard measure-
ments of diagnostic accuracy (sensitivity, specificity, and 
positive and negative predictive values) were calculated 
to determine the ability of each index test to detect sight- 
threatening eye disease. We defined sight- threatening 
eye disease as a clinically significant cataract, definite 
or suspect POAG, intermediate or advanced AMD and 
significant diabetic retinopathy (proliferative or prepro-
liferative) or diabetic maculopathy.
The unit of analysis was the individual participant and a 
comparison was made between the most abnormal index 
test from either eye and the overall reference standard 
classification. Unreliable results from the FDT and data 
from repeatedly poor- quality ORA and SD- OCT acquisi-
tions were removed from the analysis.
Binomial logistic regression was used to identify 
the index tests with significant univariate associations 
(p<0.05) with individual eye diseases. Those with signif-
icant univariate associations were included as potential 
covariates in a multivariate model using stepwise logistic 
regression. A significance level of p<0.05 was set for 
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Table 2 Eye disease identified by the reference standard 
examination
Condition n (%)
AMD
  Early 155 (30.7)
  Intermediate 27 (5.3)
  Advanced 21 (4.2)
Diabetic retinopathy
  Background 26 (5.1)
  Preproliferative 4 (0.8)
  Proliferative 2 (0.4)
  Maculopathy 5 (1.0)
POAG
  Suspect 32 (6.4)
  Definite 26 (5.1)
Cataract (clinically significant) 54 (10.7)
AMD, age- related macular degeneration; POAG, primary open- 
angle glaucoma.
entering and retaining the covariate in the final model. 
The impact of adding best- corrected visual acuity of 
<6/12 to the model was also evaluated post hoc, and the 
diagnostic performance of the final multivariate subset of 
screening tests was calculated.
All statistical analyses were performed using SPSS soft-
ware V.21.0 ( www. ibm. com/ SPSS_ Statistics) and MedCalc 
V.18.0 ( www. medcalc. org).
Patient and public involvement
There was no patient involvement in the development 
of the research question or the study design; however, 
patient networks were used in study recruitment.
resulTs
The study recruited a total of 505 subjects with a median 
age of 68 years (range 60–92). Fifty- nine per cent were 
female. Self- reported ethnicities were white (88%), South 
Asian (8%), black (2%), Chinese (1%) and ‘other’ (1%). 
Approximately 12% of the population had diabetes and 
16% reported a family history of glaucoma.
The eye diseases most commonly identified by the 
reference standard ophthalmic examination were AMD 
(n=203, 40%), definitive or suspect POAG (n=58, 12%) 
and clinically significant cataract (n=54, 11%). Based on 
the criteria from Hodapp et al,15 the 26 definitive cases 
of POAG were classified as follows: early n=11 (42%), 
moderate n=6 (23%) and advanced n=9 (35%).
Table 2 provides a summary of the prevalence of eye 
disease in our sample based on the previously described 
diagnostic criteria.
On repeat examination, 97% of the index tests were 
reliable and of sufficient quality for analysis. A total of 
195 (38.6%) participants passed all three screening tests; 
186 (36.8%) participants had one abnormal test result; 
112 (22.2%) had two abnormal results; and 12 (2.4%) 
showed an abnormality on all three tests.
The test most commonly failed was the FDT, with 193 
(38%) participants missing ≥1 location(s) at the 5% level.
logistic regression analysis
Tables 3 and 4 show the results of the univariate and 
multivariate logistic regression analyses for the associ-
ation between abnormal screening test results and the 
presence of sight- threatening eye disease. An abnormal 
FDT (based on one or more points missed at the p<5% 
or p<1% levels) was significantly associated with all target 
diseases. Visual acuity of <6/12 similarly showed univar-
iate associations with all diseases, with the exception of 
significant diabetic retinopathy/maculopathy.
An abnormal SD- OCT (one or more parameters 
outside the 99% normal limit) was associated with POAG, 
AMD and diabetic retinopathy. The strongest association 
was observed between peripapillary RNFL thickness and 
POAG. An IOP of >21 mm Hg (determined by the ORA) 
was uncommon (14%) and showed no significant asso-
ciation with any of the target conditions. The sensitivity 
and specificity of the individual tests can be found in the 
online supplementary table.
The tests that were significant (p<0.05) in the univariate 
analysis were used as candidate covariates in a stepwise 
multivariate logistic regression model (table 4). In the 
multivariate analysis, visual acuity of <6/12 was signifi-
cantly associated with a clinically significant cataract and 
AMD. An abnormal FDT at either the 5% or 1% level 
was associated with cataract and POAG, and an abnormal 
SD- OCT was predictive of POAG, AMD and diabetic reti-
nopathy. The multivariate analysis identified that visual 
acuity of <6/12, one or more locations missed at the 5% 
level on the FDT and the peripapillary RNFL thickness 
outside the 99% normal limit were predictive of sight- 
threatening eye diseases. The diagnostic performance 
of this optimised screening panel for any of the target 
conditions is summarised in table 5. The sensitivity and 
specificity of the panel were 61.3% and 78.8%, respec-
tively, with a positive predictive value of 59.5% and an 
overall diagnostic accuracy of 72.9%. Of the subjects with 
a potentially sight- threatening eye disease that would not 
have been detected using the optimised subset of tests, 
the majority were classified as either having a clinically 
significant cataract, suspect glaucoma or intermediate 
AMD. Only five participants with the most severe disease, 
definitive glaucoma (n=1), significant diabetic retinop-
athy (n=1) or advanced AMD (n=3), would have been 
missed.
dIsCussIon
The current study evaluated the predictive value of a 
panel of standard screening tests in identifying sight- 
threatening eye disease in an elderly, predominantly 
white population. We established that reduced visual 
acuity, abnormal FDT and peripapillary RNFL thickness 
outside the 99% normal limit were predictive of any 
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sight- threatening eye disease. These tests showed high 
positive and negative predictive values for the detection 
of POAG, AMD, significant diabetic retinopathy and 
clinically significant cataract, suggesting that a subset 
of screening tests could provide a basis for ophthalmic 
screening in the community. A trained technician could 
easily conduct these tests, and screen- positive individuals 
could then be referred for a full ophthalmic assessment.
Kopplin and Mansberger11 have similarly shown that 
ophthalmic technicians could effectively identify visually 
significant eye disease in a cohort of American Indian 
and Alaskan Native participants using a similar battery 
of screening tests. The test combination used in this 
study had a sensitivity of 94% and a specificity of 32%. 
By contrast, the sensitivity and specificity of the screening 
panel used in the current study were 61% and 79%, 
respectively, with similar positive and negative predictive 
values (60% and 80%). Although the screening panel 
failed to identify approximately a third of subjects with 
cataract, suspect glaucoma and intermediate AMD, over 
90% of those with the most severe disease were detected.
An earlier UK study investigated the cost- effectiveness 
of a similar ‘technician screening’ model for POAG 
in a population aged >40 years, compared with the 
current opportunistic case finding strategy.16 The 
authors concluded that screening was unlikely to be 
cost- effective, based on a comparison of the incremental 
cost- effectiveness ratio to a standard threshold of a soci-
etal willingness to pay of £30 000 per quality- adjusted life 
year. However, a sensitivity analysis showed that the cost- 
effectiveness of screening for POAG was highly dependent 
on disease prevalence. For example, at a prevalence of 
5%, the technician screening model became more cost- 
effective than current practice. The cost- effectiveness of 
population screening for eye disease could be increased 
by either screening a group with a higher prevalence of a 
target condition or extending the screening programme 
to encompass several diseases. In the current study, the 
prevalence of sight- threatening eye disease in our elderly 
participants was in the region of 30%, and therefore, 
technician screening for significant eye disease in this 
population is highly likely to be cost- effective. Further-
more, our model could provide a screening template for 
the detection of significant eye disease in underserved 
populations. Although at a higher risk of eye disease, 
people from minority ethnic groups and those from 
lower socioeconomic groups are less likely to access eye 
care services and consequently are at a greater risk of late 
presentation with associated poorer outcomes.17–20
The index tests used were designed to detect struc-
tural and/or functional defects. The first- generation 
FDT perimeter in the C-20–5 suprathreshold mode 
was used to evaluate visual function and determines 
contrast thresholds at 17 locations within the central 20 
degrees of the visual field. Stimuli are initially presented 
at a contrast level that should be detected by 95% of 
age- matched normal subjects. This test was originally 
developed for glaucoma screening; however, the FDT has 
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Table 4 Multivariate stepwise logistic regression analysis of abnormal screening results with significant ocular disease
Clinically 
significant 
cataract POAG (definite)
POAG (definite 
and suspect)
Age related 
macular 
degeneration 
(AMD)
Significant diabetic 
retinopathy/maculopathy
Any sight- 
threatening eye 
disease
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Visual acuity<6/12 5.53
(2.91 to 10.54)
NS NS 4.49
(2.40 to 8.41)
NS 4.12
(2.26 to 7.52)
Family history of 
glaucoma
NS 4.75
(1.51 to 14.92)
2.50
(1.20 to 5.20)
NS NS NS
IOP>21 mm Hg NS NS NS NS NS NS
FDT≥1 point missed 
at 1% level
NS 8.55
(2.22 to 32.96)
3.93
(2.05 to 7.53)
NS NS NS
FDT≥1 point missed 
at 5% level
2.60
(1.40 to 4.84)
NS NS NS NS 3.62
(2.38 to 5.51)
SD- OCT (GCC 
thickness)
NS 5.52
(1.57 to 19.41)
NS NS NS NS
SD- OCT (full retinal 
thickness)
NS NS NS NS 17.86
(2.18 to 146.47)
NS
SD- OCT (peripapillary 
RNFL thickness)
NS 9.10
(2.85 to 28.96)
11.98
(5.61 to 25.60)
3.81
(1.74 to 8.35)
NS 5.24
(2.45 to 11.24)
FDT, frequency- doubling technology;GCC, ganglion cell complex; IOP, intraocular pressure; NS, not significant; POAG, primary open- 
angle glaucoma; RNFL, retinal nerve fibre layer; SD- OCT, spectral domain optical coherence tomography.
Table 5 Diagnostic performance of the optimised panel of 
screening tests (SD- OCT, FDT and measurement of visual 
acuity) in identifying sight- threatening eye disease
Value (95% CI)
Sensitivity (%) 61.3 (53.5 to 68.7)
Specificity (%) 78.8 (74 to 83.1)
Positive likelihood ratio 2.9 (2.3 to 3.7)
Negative likelihood ratio 0.5 (0.40 to 0.60)
Disease prevalence (%) 33.7 (29.6 to 39.1)
Positive predictive value (%) 59.5 (53.7 to 65.2)
Negative predictive value (%) 80.0 (76.6 to 83.0)
Overall accuracy (%) 72.9 (68.8 to 76.8)
also been shown to be effective for the detection other 
eye diseases.21 An abnormal FDT result showed a univar-
iate association with all target conditions and a threshold 
of ≥1 point missed at the 5% level was retained in the 
final multivariate model. Similarly, an abnormality in 
one or more SD- OCT parameters showed a univariate 
association with POAG, AMD and diabetic retinopathy. 
The OCT parameters selected for the analysis and the 
associated pass/fail criteria (value outside the 99% CI 
based on the iVue SD- OCT normative database) were 
established a priori. Thinning of the peripapillary RNFL 
showed the strongest association, and this parameter was 
retained in the final model. Predictably, the association 
was strongest for POAG, but a statistically significant asso-
ciation was also found for AMD. While the OCT is widely 
used as a diagnostic tool for neovascular AMD, where it is 
particularly effective in detecting subretinal fluid,22 more 
recently, morphological changes in the inner retina have 
been documented in eyes with AMD. Changes in the 
thickness of the GCC and RNFL have been reported in 
both atrophic and neovascular forms of AMD.23 24
In the UK and internationally, there has been a shift 
towards integrating advanced imaging technologies, 
particularly OCT, into routine case finding.25–28 Global 
interest in the value of SD- OCT for detecting retinal 
disease has recently been fuelled further by the applica-
tion of artificial intelligence (AI) based on deep learning 
algorithms.29 30 Applying AI to a set of real- world OCT 
scans, taken from patients referred into a large tertiary 
referral centre, showed a diagnostic performance that 
was comparable and, in some cases, better than clinical 
experts for a range of sight- threatening retinal diseases.
strengths and limitations
To our knowledge, this is the first UK study that has evalu-
ated the performance of a combination of screening tests 
to detect clinically significant eye diseases in a primary 
care setting. The study has a number of strengths. The 
design, analysis and reporting complied with the prin-
ciples of the Standards for Reporting of Diagnostic 
Accuracy statement.31 To reduce spectrum bias, the 
target population included consecutive subjects who 
met the inclusion criteria, and there were no exclusions. 
Although it is possible that higher numbers of those with 
a personal or family history of eye disease were more 
likely to agree to participate in the study, the prevalence 
of sight- threatening eye disease in our population (30%) 
was similar to a London- based cross- sectional study that 
used random sampling.14 Therefore, we believe that the 
study sample is likely to be broadly representative of the 
 o
n
 M
arch 2, 2020 by guest. Protected by copyright.
http://bmjophth.bmj.com/
BM
J O
pen O
phth: first published as 10.1136/bmjophth-2019-000347 on 4 December 2019. Downloaded from 
7Fidalgo BR, et al. BMJ Open Ophth 2019;4:e000347. doi:10.1136/bmjophth-2019-000347
Open access
local population. The reference standard used to clas-
sify the participants’ ocular status corresponded to that 
used in a typical hospital eye clinic and was based on 
the results of a standard ophthalmic examination by a 
validated clinician. All index tests and the reference stan-
dard examination were undertaken on the same day, and 
the clinician performing the reference examination and 
the ophthalmic technician undertaking the index tests 
were masked to the results.
The study also has some limitations. Although a large 
sample of the population was examined, the prevalence 
of the individual target conditions was low, and conse-
quently, the reported measures of index test performance 
were associated with wide confidence intervals. Further-
more, since the identified panel of screening tests was 
not tested on an independent validation sample, it is 
possible that the predicative value of these tests may be 
lower in other populations. Approximately 90% of our 
study population was of white European origin, and 
therefore, our findings may not be generalisable to other 
ethnic groups.
The current study did not include a formal cost- 
effectiveness analysis. One of the tenets of Wilson and 
Jungner’s widely implemented ‘Principles and Practice 
of Screening for Disease’32 states that ‘the cost of case- 
finding (including diagnosis and treatment of patients 
diagnosed) should be economically balanced in relation 
to possible expenditure on medical care as a whole.’ 
An economic evaluation of any proposed screening 
programme is therefore essential to assess the full costs of 
implementing, operating and sustaining the programme. 
Recent studies in ophthalmology have recognised the 
efficiencies gained in screening for more than one eye 
condition. For example, AMD screening carried out 
simultaneously with digital screening for diabetic retinop-
athy is cost- effective in the context of a public healthcare 
system in Hong Kong.33
ConClusIons
Our study has demonstrated the feasibility of using a panel 
of standard screening tests performed by an ophthalmic 
technician to detect sight- threatening eye disease in a 
representative sample of the elderly population. The 
results provide useful data to inform the development 
of larger, multicentre population studies to evaluate the 
effectiveness and cost- effectiveness of screening for eye 
disease in the elderly.
Acknowledgements The authors thank Optovue for the loan of the iVue optical 
coherence tomographer.
Contributors BRF: study design and conception, collection of data, data analysis 
and interpretation, writing of the manuscript and approval; PD: study design and 
conception, collection of data, data analysis and approval; AJ, IC and TP: data 
analysis and interpretation and approval; DFE: study design and conception, data 
analysis and interpretation, and approval; JGL: study design and conception, data 
analysis and interpretation, writing of the manuscript and approval.
Funding The study was funded by the College of Optometrists UK.
Competing interests None declared.
Patient consent for publication Not required.
ethics approval The study was approved by the research and ethical committee of 
the Division of Optometry and Visual Science, City, University of London (reference 
number 189A.4b) and adhered to the tenets of the Declaration of Helsinki. Informed 
written consent was obtained prior to participation.
Provenance and peer review Not commissioned; externally peer reviewed.
data availability statement All data relevant to the study are included in the 
article or uploaded as supplementary information.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the 
use is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
orCId ids
Bruno R Fidalgo https:// orcid. org/ 0000- 0003- 1134- 2148
Anish Jindal https:// orcid. org/ 0000- 0002- 1200- 9438
Irene Ctori http:// orcid. org/ 0000- 0003- 1523- 4996
John G Lawrenson http:// orcid. org/ 0000- 0002- 2031- 6390
reFerenCes
 1 Pezzullo L, Streatfeild J, Simkiss P, et al. The economic impact of 
sight loss and blindness in the UK adult population. BMC Health 
Serv Res 2018;18:63.
 2 Evans BJW, Rowlands G. Correctable visual impairment in older 
people: a major unmet need. Oph Phys Optics 2004;24:161–80.
 3 RNIB. Future sight loss UK (1): the economic impact of partial sight 
and blindness in the UK adult population, 2009. Available: https://
www. rnib. org. uk/ sites/ default/ files/ FSUK_ Report. pdf[Accessed 8 
May 2019].
 4 Boodhna T, Crabb DP. Disease severity in newly diagnosed 
glaucoma patients with visual field loss: trends from more than a 
decade of data. Ophthalmic Physiol Opt 2015;35:225–30.
 5 Lane M, Mathewson PA, Sharma HE, et al. Social deprivation as a 
risk factor for late presentation of proliferative diabetic retinopathy. 
Clin Ophthalmol 2015;9:347–52.
 6 WHO. Towards universal eye health: a global action plan 2014–2019 
(WHA66.4), 2013. Available: http:// apps. who. int/ gb/ ebwha/ pdf_ files/ 
WHA66- REC1/ A66_ REC1- en. pdf? ua=1 [Accessed 8 May 2019].
 7 Ariyasu RG, Lee PP, Linton KP, et al. Sensitivity, specificity, and 
predictive values of screening tests for eye conditions in a clinic- 
based population. Ophthalmology 1996;103:1751–60.
 8 Wang F, Tielsch JM, Ford DE, et al. Evaluation of screening schemes 
for eye disease in a primary care setting. Ophthalmic Epidemiol 
1998;5:69–82.
 9 Ivers RQ, Macaskill P, Cumming RG, et al. Sensitivity and specificity 
of tests to detect eye disease in an older population. Ophthalmology 
2001;108:968–75.
 10 Boland MV, Gupta P, Ko F, et al. Evaluation of frequency- doubling 
technology perimetry as a means of screening for glaucoma 
and other eye diseases using the National health and nutrition 
examination survey. JAMA Ophthalmol 2016;134:57–62.
 11 Kopplin LJ, Mansberger SL. Predictive value of screening tests for 
visually significant eye disease. Am J Ophthalmol 2015;160:538–46.
 12 Dabasia PL, Fidalgo BR, Edgar DF, et al. Diagnostic accuracy of 
technologies for glaucoma case- finding in a community setting. 
Ophthalmology 2015;122:2407–15.
 13 Mowatt G, Burr JM, Cook JA, et al. Screening tests for detecting 
open- angle glaucoma: systematic review and meta- analysis. Invest 
Ophthalmol Vis Sci 2008;49:5373–85.
 14 Reidy A, Minassian DC, Vafidis G, et al. Prevalence of serious 
eye disease and visual impairment in a North London population: 
population based, cross sectional study. BMJ 1998;316:1643–6.
 15 Hodapp E, Parrish RK, Anderson DR. Clinical decisions in glaucoma. 
St. Louis, MO: The CV Mosby Co, 1993: 52–61.
 16 Hernández RA, Burr JM, Vale LD, et al. Economic evaluation of 
screening for open- angle glaucoma. Int J Technol Assess Health 
Care 2008;24:203–11.
 17 Dickey H, Ikenwilo D, Norwood P, et al. Utilisation of eye- care 
services: the effect of Scotland's free eye examination policy. Health 
Policy 2012;108:286–93.
 18 Gulliford MC, Dodhia H, Chamley M, et al. Socio- Economic and 
ethnic inequalities in diabetes retinal screening. Diabet Med 
2010;27:282–8.
 o
n
 M
arch 2, 2020 by guest. Protected by copyright.
http://bmjophth.bmj.com/
BM
J O
pen O
phth: first published as 10.1136/bmjophth-2019-000347 on 4 December 2019. Downloaded from 
8 Fidalgo BR, et al. BMJ Open Ophth 2019;4:e000347. doi:10.1136/bmjophth-2019-000347
Open access
 19 Fraser Set al. Deprivation and late presentation of glaucoma: case- 
control study. BMJ 2001;322:639–43.
 20 Ng WS, Agarwal PK, Sidiki S, et al. The effect of socio- economic 
deprivation on severity of glaucoma at presentation. Br J Ophthalmol 
2010;94:85–7.
 21 Cioffi GA, Mansberger S, Spry P, et al. Frequency doubling perimetry 
and the detection of eye disease in the community. Trans Am 
Ophthalmol Soc 2000;98:195–9.
 22 Ouyang Y, Heussen FM, Keane PA, et al. The retinal disease 
screening study: prospective comparison of nonmydriatic fundus 
photography and optical coherence tomography for detection of 
retinal irregularities. Invest Ophthalmol Vis Sci 2013;54:1460–8.
 23 Zucchiatti I, Parodi MB, Pierro L, et al. Macular ganglion cell 
complex and retinal nerve fiber layer comparison in different 
stages of age- related macular degeneration. Am J Ophthalmol 
2015;160:602–7.
 24 Lee EK, Yu HG. Ganglion Cell- Inner plexiform layer and peripapillary 
retinal nerve fiber layer thicknesses in age- related macular 
degeneration. Invest Ophthalmol Vis Sci 2015;56:3976–83.
 25 Jamous KF, Kalloniatis M, Hayen A, et al. Application of clinical 
techniques relevant for glaucoma assessment by optometrists: 
concordance with guidelines. Ophthalmic Physiol Opt 
2014;34:580–91.
 26 Dabasia PL, Edgar DF, Garway- Heath DF, et al. A survey of current 
and anticipated use of standard and specialist equipment by UK 
optometrists. Ophthalmic Physiol Opt 2014;34:592–613.
 27 Ly A, Nivison- Smith L, Zangerl B, et al. Self- Reported optometric 
practise patterns in age- related macular degeneration. Clin Exp 
Optom 2017;100:718–28.
 28 Kiely PM, Cappuccio S, McIntyre E. Optometry Australia scope of 
practice survey 2015. Clin Exp Optom 2017;100:260–9.
 29 Ting DSW, Pasquale LR, Peng L, et al. Artificial intelligence 
and deep learning in ophthalmology. Br J Ophthalmol 
2019;103:167–75.
 30 De Fauw J, Ledsam JR, Romera- Paredes B, et al. Clinically 
applicable deep learning for diagnosis and referral in retinal disease. 
Nat Med 2018;24:1342–50.
 31 Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD statement 
for reporting studies of diagnostic accuracy: explanation and 
elaboration. Ann Intern Med 2003;138:W1–12.
 32 Wilson JMG, Jungner G. Principles and practice of screening for 
disease. Geneva: World Health Organization, 1968. https:// apps. 
who. int/ iris/ handle/ 10665/ 37650
 33 Chan CKW, Gangwani RA, McGhee SM, et al. Cost- effectiveness 
of screening for intermediate age- related macular degeneration 
during diabetic retinopathy screening. Ophthalmology 
2015;122:2278–85.
 34 Ferris FL, Davis MD, Clemons TE, et al. A simplified severity scale 
for age- related macular degeneration: AREDS report No. 18. Arch 
Ophthalmol 2005;123:1570–4.
 35 Chylack LTet al. Lens opacities classification system II (LOCS II). 
Arch Ophthal 1989;107:991–7.
 o
n
 M
arch 2, 2020 by guest. Protected by copyright.
http://bmjophth.bmj.com/
BM
J O
pen O
phth: first published as 10.1136/bmjophth-2019-000347 on 4 December 2019. Downloaded from 
